All In Biotech

Drug Trial Radar · NCT06122922

Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN)

Xenon MRI in Stable Patients With Pulmonary Hypertension

Last checked: Nov 20, 2026Latest source record: Jan 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Mar 15, 2024

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Bastiaan DriehuysAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Regeneron Pharmaceuticals
First posted
Nov 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this project is to determine how pulmonary vascular remodeling in Pulmonary Arterial Hypertension (PAH) at cellular and pathological level is associated with gas exchange physiology changes and hemodynamics (monitored with 129Xe MRI/MRS) and how these signals change with disease progression or treatment.

Conditions

  • Pulmonary Artery Hypertension

Interventions

  • Hyperpolarized Xe129Drug

    Hyperpolarized Xenon Gas

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in pulmonary vascular functionTime frame: Baseline, 3 months, 6 months, 1 year
  2. Change in pulmonary vascular functionTime frame: Baseline, 3 months, 6 months, 1 year
  3. Change in pulmonary vascular functoinTime frame: Baseline, 3 months, 6 months, 1 year

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.